Type 1 Diabetes
Type 1 Diabetes (T1D) is a lifelong autoimmune disease where the pancreas does not produce any insulin, resulting from the body mistakenly attacking the insulin-producing beta-cells in the pancreas.
Insulin is a vital hormone that helps regulate the body’s blood sugar levels.
This leads to life-long insulin dependence.
Current Landscape
Insulin treats symptoms only
New technologies (e.g. CGM and insulin pumps) still can’t perfectly control blood sugar levels
The only disease-modifying drug, TZIELD, is indicated for Stage 2 T1D and can delay T1D by two years¹
No therapy to preserve a person’s own beta-cells, which enables stable glucose control and reduces insulin dependence.
Why it Matters
Daily risk of fatal hypoglycaemia (low blood sugar)
Lifelong complications including amputation, organ failure, and blindness
Reduced life expectancy by up to 24 years globally²
Our immune tolerance approach could allow a person’s own beta-cells to regulate their blood sugar without the use of insulin.
Sanofi Canada. (2025, May 5). Health Canada has granted approval for Tzield®, the first and only disease-modifying therapy in autoimmune type 1 diabetes in Canada [Press release].
Gregory, G. A., et al. (2022). Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. The Lancet Diabetes & Endocrinology, 10(10), 741–760. https://doi.org/10.1016/S2213-8587(22)00218-2
Ogle, G. D., et al. (2025). Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Research and Clinical Practice, 225(112277). https://doi.org/10.1016/j.diabres.2025.112277.
Centers for Disease Control and Prevention. (2026, January 20). National diabetes statistics report. [Webpage]
Sanofi. (2023, March 13). Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for people at risk for type 1 diabetes. [Press release].